Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

Background The absence of the putative DNA/RNA helicase Schlafen11 (SLFN11) is thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. Methods We developed and validated a clinically applicable SLFN11 immunohistochemistry assay and retrospectively correlated SLFN11 tumour leve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2021-12, Vol.125 (12), p.1666-1676
Hauptverfasser:	Willis, Sophie E., Winkler, Claudia, Roudier, Martine P., Baird, Tarrion, Marco-Casanova, Paola, Jones, Emma V., Rowe, Philip, Rodriguez-Canales, Jaime, Angell, Helen K., Ng, Felicia S. L., Waring, Paul M., Hodgson, Darren, Ledermann, Jonathan A., Weberpals, Johanne I., Dean, Emma, Harrington, Elizabeth A., Barrett, J. Carl, Pierce, Andrew J., Leo, Elisabetta, Jones, Gemma N.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1857 692/4028/67/1857 Animals Biomarkers Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Deoxyribonucleic acid DNA DNA damage DNA Damage - genetics DNA helicase Drug Resistance Epidemiology Etoposide Female Humans Immunohistochemistry Male Medical prognosis Mice Mice, Nude Molecular Medicine Multivariate analysis Nuclear Proteins - metabolism Oncology Ovarian cancer Paclitaxel Patients Placebos Platinum Poly(ADP-ribose) polymerase Retrospective Studies RNA helicase Survival Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!